MET and neoplasm: Besides, the National Comprehensive Cancer Network (NCCN) guidelines for NSCLC (2019, version 4) advocate testing of the tumor tissue to optimally identify mutations in EGFR, KRAS, HER2, ALK, ROS1, MET, BRAF, RET, and NTRK genes [100].